IndiaNovo Nordisk has introduced Awiqli, the world's first once-weekly basal insulin, in India, aiming to simplify diabetes treatment by reducing weekly injections from 365 per year to just 52. This therapy addresses injection anxiety and improves adherence among adults with Type 1 and Type 2 diabetes. India has nearly 10.1 crore people with diabetes and 13.6 crore with prediabetes, with over 9 lakh suffering from Type 1 diabetes requiring insulin therapy. Awiqli is administered via a weekly pen device called FlexTouch, potentially encouraging earlier insulin initiation and improving health outcomes. Clinical trials show it reduces HbA1c levels effectively while maintaining safety. The launch highlights India's growing diabetes burden and Novo Nordisk's leadership in diabetes care.
Bias read (Center): The article presents information about a medical innovation without overt ideological framing. While the topic relates to healthcare policy and public health, the focus is on scientific advancement and patient benefits rather than partisan debate. The tone remains neutral, emphasizing clinical data,
